Trials / Completed
CompletedNCT00273416
A Randomized Double Blind, Placebo Controlled Balanced 4-Way Crossover Study To Assess The Efficacy Of Single Oral Doses
A Randomized Double Blind, Placebo Controlled Balanced 4-Way Crossover Study To Assess The Efficacy Of Single Oral Doses Of PF-00592379 On Erectile Function, Using 100mg Sildenafil As A Positive Control
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 32 (planned)
- Sponsor
- Pfizer · Industry
- Sex
- Male
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The primary aim of this study is to assess how effective PF-00592379 is in restoring penile erections in patients with erectile dysfunction. Patients will attend for 4 treatment visits where they will receive the following in random order; 2 separate doses of PF-00592379, sildenafil 100mg used as a positive control, or placebo (dummy medication). The effect on penile erections will be assessed in the clinic using penile plethysmography (RigiScan PlusTM technique).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PF-00592379 | |
| DRUG | Sildenafil 100mg |
Timeline
- Start date
- 2006-01-01
- First posted
- 2006-01-09
- Last updated
- 2006-08-24
Locations
2 sites across 2 countries: Norway, United Kingdom
Source: ClinicalTrials.gov record NCT00273416. Inclusion in this directory is not an endorsement.